
    
      This is a randomized, double-blind, placebo-controlled, parallel-group study designed to
      evaluate the efficacy, safety and tolerability of SD-809 for the treatment of chorea
      associated with Huntington's Disease. Approximately 90 subjects will be randomized (1:1) into
      the study, with approximately 45 subjects receiving SD-809 and 45 subjects receiving placebo.
      The study will be conducted at approximately 30 centers in the U.S. and Canada.
    
  